Sharda Cropchem Ltd Valuation Turns Attractive Amid Strong Market Outperformance

Valuation Metrics Signal Renewed Attractiveness

Recent analysis reveals that Sharda Cropchem’s price-to-earnings (P/E) ratio stands at 18.25, a level that is notably lower than many of its industry peers, signalling a more reasonable price point relative to earnings. This compares favourably against Bayer CropScience’s P/E of 35.29 and BASF India’s 43.69, both of which are classified as expensive despite their larger scale. The company’s price-to-book value (P/BV) is 3.86, reflecting a moderate premium over book value but still within an attractive range for investors seeking growth at a reasonable price.

Enterprise value to EBITDA (EV/EBITDA) ratio of 10.70 further underscores the stock’s valuation appeal, especially when juxtaposed with peers such as Anupam Rasayan, which trades at a lofty 30.86 EV/EBITDA, and Bhagiradha Chemicals at an extraordinary 70.21. These metrics collectively suggest that Sharda Cropchem is trading at a discount relative to its earnings and cash flow generation capacity, making it an enticing proposition for value-conscious investors.

Strong Financial Performance Supports Valuation

Sharda Cropchem’s return on capital employed (ROCE) is an impressive 24.83%, indicating efficient utilisation of capital to generate profits. Its return on equity (ROE) of 16.89% also reflects solid shareholder returns, reinforcing the company’s operational strength. The PEG ratio, a measure of valuation relative to earnings growth, is exceptionally low at 0.14, signalling that the stock is undervalued relative to its growth prospects.

Dividend yield stands at 1.05%, offering a modest income stream alongside capital appreciation potential. The company’s enterprise value to capital employed ratio of 5.03 and EV to sales of 1.90 further highlight its balanced valuation profile, combining growth with reasonable pricing.

Market Performance Outpaces Benchmarks

Sharda Cropchem’s stock price has demonstrated remarkable resilience and growth over multiple time horizons. Year-to-date, the stock has surged 30.92%, contrasting sharply with the Sensex’s decline of 1.16%. Over the past year, the stock has more than doubled, delivering a 105.15% return compared to the Sensex’s 10.41%. The longer-term performance is even more striking, with five-year and ten-year returns of 284.69% and 429.20% respectively, dwarfing the Sensex’s 63.46% and 267.00% gains over the same periods.

Such outperformance reflects strong investor confidence in the company’s growth trajectory and the broader agrochemical sector’s resilience amid evolving agricultural demands and regulatory environments.

Comparative Industry Valuation Landscape

Within the Pesticides & Agrochemicals sector, Sharda Cropchem’s valuation stands out as particularly attractive. While companies like Bayer CropScience and Laxmi Organic are trading at expensive multiples, Sharda Cropchem’s metrics suggest a more compelling risk-reward balance. Rallis India and Bharat Rasayan also fall into the attractive category, but their P/E ratios of 26.72 and 21.00 respectively remain higher than Sharda Cropchem’s 18.25.

Conversely, firms such as Anupam Rasayan and Bhagiradha Chemicals are classified as very expensive, with P/E ratios exceeding 100 and 200 respectively, indicating stretched valuations that may not be justified by fundamentals. Dhanuka Agritech’s fair valuation and NACL Industries’ risky status due to loss-making operations further highlight the diverse valuation spectrum within the sector.

Recent Market Movements and Price Action

On 12 Feb 2026, Sharda Cropchem’s stock closed at ₹1,144.65, down 2.14% from the previous close of ₹1,169.65. The day’s trading range was between ₹1,116.95 and ₹1,183.80, with the 52-week high at ₹1,226.00 and low at ₹440.05. Despite the slight intraday dip, the stock remains near its upper price band for the year, reflecting sustained investor interest.

Such price action, combined with the company’s strong fundamentals and attractive valuation, suggests that the recent correction may offer a buying opportunity for investors seeking exposure to a high-quality agrochemical player with robust growth prospects.

Mojo Score Upgrade Reflects Confidence

MarketsMOJO has upgraded Sharda Cropchem’s Mojo Grade from Buy to Strong Buy as of 29 Oct 2025, reflecting enhanced confidence in the company’s outlook. The Mojo Score of 84.0 places it among the top-rated small caps in the sector, signalling strong fundamental quality and favourable risk-reward dynamics. The market capitalisation grade remains at 3, indicating a mid-sized company with significant growth potential.

Investment Outlook and Considerations

Sharda Cropchem’s transition to an attractive valuation grade is underpinned by solid earnings growth, efficient capital deployment, and a valuation discount relative to peers. The company’s PEG ratio of 0.14 is particularly compelling, indicating that the stock’s price has not yet fully reflected its earnings growth potential.

Investors should note, however, that the agrochemical sector is subject to regulatory risks, commodity price fluctuations, and seasonal demand variability. While Sharda Cropchem’s fundamentals are robust, these external factors could impact near-term performance.

Nonetheless, the company’s consistent outperformance against the Sensex and its peers over multiple time frames, combined with the recent upgrade to a Strong Buy rating, suggest that it remains well-positioned to deliver attractive returns over the medium to long term.

Conclusion

In summary, Sharda Cropchem Ltd’s valuation has shifted favourably, offering investors an attractive entry point supported by strong financial metrics and superior market performance. Its P/E and EV/EBITDA ratios are significantly more reasonable than many sector peers, while its return ratios and growth prospects remain robust. The recent Mojo Grade upgrade to Strong Buy further validates the company’s investment appeal.

For investors seeking exposure to the Pesticides & Agrochemicals sector, Sharda Cropchem presents a compelling blend of growth, quality, and valuation that merits close consideration.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →